Suggested remit - To appraise the clinical and cost effectiveness of netarsudil within its marketing authorisation for treating open angle glaucoma or ocular hypertension.
The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
- Status:
- Suspended
- Decision:
- None selected
- Process:
- TA
- ID number:
- 1078
Project Team
- Project lead
- Michelle Adhemar
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 24 June 2026 | Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
| 05 August 2020 - 03 September 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 18 December 2018 | Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual